EUVIMEDEUVIMED entdecken
Vergleichsstudie

Vismodegib and Sonidegib Are Associated With an Elevated Reporting Odds of Squamous Cell Carcinoma; a Comparative Pharmacovigilance Study of the FDA Adverse Events Reporting System ( FAERS )

Patrick Jedlowski iD, Alexander Rose iD, Jason DuPont

Australasian Journal of Dermatology · 2025

DOI: 10.1111/ajd.70016 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Australasian Journal of Dermatology, 2025. Verfasst von Patrick Jedlowski und 2 weiteren Autor:innen. Beteiligte Einrichtung: Unersity of Arizona College of Medicine - Tucson, Division of Dermatology, Tucson, Arizona, USA. Hauptthemen laut MEDLINE: Pyridines, Carcinoma, Squamous Cell, Anilides, Skin Neoplasms. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Direct comparison of the adverse effect (AE) profiles of the hedgehog inhibitor (HIs) medications is limited to post hoc analyses of phase III clinical trials.

Objective

Compare the AE profiles between vismodegib and sonidegib in the FDA Adverse Event Reporting System (FAERS).

Methods

Case/non‐case analyses were performed in FAERS and reporting odds ratios (ROR) were compared to determine unique and disproportionate AEs between HIs.

Results

Vismodegib had significantly higher ROR for taste symptoms and alopecia. Sonidegib was associated with neutropenia and elevated blood creatinine phosphokinase. Both vismodegib and sonidegib were associated with an increased ROR for cSCC (50.36 [42.36–59.86] vs. 50.28 [27.71–91.23]). This signal persisted despite comparison to an aggregate of other medications used to treat basal cell carcinoma (BCC) (11.56 [9.51–14.05] vs. 9.71 [1.25–75.43]).

Limitations

Retrospective nature predisposed to bias.

Conclusions

Vismodegib has a significantly higher ROR for alopecia and taste symptoms, while sonidegib was associated with neutropenia, which is a novel finding. Both HIs are associated with an increased ROR for cSCC, which persists despite stringent controls and does not parallel total cSCC cases reported to FAERS. These data suggest that HIs increase the risk of cSCC above the baseline expected in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridinesCarcinoma, Squamous CellAnilidesSkin NeoplasmsBiphenyl CompoundsAntineoplastic AgentsHumansUnited StatesAdverse Drug Reaction Reporting SystemsUnited States Food and Drug AdministrationPharmacovigilanceAlopeciaMaleFemaleMiddle AgedAgedBasal Cell CarcinomaNeutropeniaTaste DisordersRetrospective Studies

Stichwörter der Autor:innen

ageusiaalopeciamyalgiapharmacovigilancesonic hedgehog inhibitorssonidegibsquamous cell carcinomavismodegib

Substanzen

PyridinesHhAntag691AnilidessonidegibBiphenyl CompoundsAntineoplastic Agents

Autor:innen und Institutionen

  • Unersity of Arizona College of Medicine - Tucson, Division of Dermatology, Tucson, Arizona, USA.

ORCID-Profile: Patrick Jedlowski, Alexander Rose

Zitieren

APA

Jedlowski, P., Rose, A., & DuPont, J. (2025). Vismodegib and Sonidegib Are Associated With an Elevated Reporting Odds of Squamous Cell Carcinoma; a Comparative Pharmacovigilance Study of the FDA Adverse Events Reporting System ( FAERS ). Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.70016

Vancouver

Jedlowski P, Rose A, DuPont J. Vismodegib and Sonidegib Are Associated With an Elevated Reporting Odds of Squamous Cell Carcinoma; a Comparative Pharmacovigilance Study of the FDA Adverse Events Reporting System ( FAERS ). Australasian Journal of Dermatology. 2025. doi:10.1111/ajd.70016

BibTeX
@article{Jedlowski2025,
  author = {Jedlowski, Patrick and Rose, Alexander and DuPont, Jason},
  title = {Vismodegib and Sonidegib Are Associated With an Elevated Reporting Odds of Squamous Cell Carcinoma; a Comparative Pharmacovigilance Study of the FDA Adverse Events Reporting System ( FAERS )},
  journal = {Australasian Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ajd.70016}
}
Kostenlos starten →